PRTK VS JNJ Stock Comparison
Performance
PRTK10/100
10/100
PRTK returned -12.00% in the last 12 months. Based on SPY's performance of -7.13%, its performance is below average giving it a score of 10 of 100.
JNJ73/100
73/100
JNJ returned -15.84% in the last 12 months. Based on SPY's performance of -20.60%, its performance is above average giving it a score of 73 of 100.
Analyst Price Targets
PRTK93/100
93/100
10 analysts offer 12-month price targets for PRTK. Together, they have an average target of 20, the most optimistic target put PRTK at 20 within 12-months and the most pessimistic has PRTK at 20. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.
JNJ63/100
63/100
23 analysts offer 12-month price targets for JNJ. Together, they have an average target of 176.5, the most optimistic target put JNJ at 205 within 12-months and the most pessimistic has JNJ at 90.
Sentiment
PRTK69/100
69/100
PRTK had a bullish sentiment score of 69.17% across Twitter and StockTwits over the last 12 months. It had an average of 8.91 posts, 3.68 comments, and 7.87 likes per day.
JNJ72/100
72/100
JNJ had a bullish sentiment score of 71.87% across Twitter and StockTwits over the last 12 months. It had an average of 205.31 posts, 3,341.61 comments, and 16,552.61 likes per day.
Technicals
PRTK86/100
86/100
PRTK receives a 85 of 100 based on 14 indicators. 11 are bullish, 1 are bearish.
JNJ14/100
14/100
JNJ receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
PRTK10/100
10/100
PRTK has missed earnings 7 times in the last 20 quarters.
JNJ100/100
100/100
JNJ has missed earnings 0 times in the last 20 quarters.
Profit
PRTK10/100
10/100
Out of the last 20 quarters, PRTK has had 1 profitable quarters and has increased their profits year over year on 1 of them.
JNJ74/100
74/100
Out of the last 20 quarters, JNJ has had 19 profitable quarters and has increased their profits year over year on 9 of them.
Volatility
PRTK49/100
49/100
PRTK has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
JNJ43/100
43/100
JNJ has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.
Dividend
PRTK
"Dividend" not found for PRTK
JNJ100/100
100/100
JNJ's most recent dividend was $0.90 per share, based on a share price of $145.60. It was a payout ratio of 61.39% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
Paratek Pharmaceuticals, Inc. Summary
Nasdaq / PRTK
Healthcare
Biotechnology
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Johnson & Johnson Summary
New York Stock Exchange / JNJ
Healthcare
Drug Manufacturers - General
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare PRTK to other companies in the same or a similar industry.